PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.
FAIL · Does not pass the screen
64.13 USD
Screen close, 2026-10-01 · not a live quote Last reviewed 6 days ago
Screened 2026-10-01 · the tape above runs as of 01:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 64.13 against the desk's fair-value range, base estimate 79.94, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price64.13 USD
Fair value79.94
Ethical score70.0/100
Our investment reviews on this name
2026-09-10Read Markdown73.47-12.7% to today ✓
2026-07-02Read Markup75.14-14.7% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
PTC Therapeutics, Inc. holds its Markdown at $64.13. The statistical read favours the sellers, held for 13 days.
As held on the ledger · 2026-10-01
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 13 days
Price at the screen
$64.13
Valuation
N/A trailing · 23.96 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.55
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
93.39%
Below 33%
Interest-bearing debt is 93.4% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
33.14%
Below 33%
Cash held in interest-bearing accounts and securities is 33.1% of assets, under the one-third limit.
Pass
Receivables
40.23%
Below 49%
Money owed to the company is 40.2% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
PTC Therapeutics,'s business is in a permissible area, but its interest-bearing debt is about 93% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-07. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-01 screen. The gold marker is the market price at the same screen. A 24.7% margin of safety to the base estimate.
Third-party analyst targets: 14 covering, consensus Buy. The average target sits +57% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-01 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Rare disease biotech trades well above fair value
Imagine pouring money into a lab that promises treatments for children with rare genetic disorders, only to watch sales collapse and losses widen. That picture fits here, where revenue has dropped 77 percent and margins sit at negative 23 percent.
The stock trades at 25.5 times forward earnings, a 22 percent premium to our fair value of 61 dollars. With no opportunity rating and an ethical screen that simply passes, the numbers give us no reason to engage despite the buy rating from fourteen analysts.
Execution in narrow patient populations carries heavy clinical and regulatory risk, and the gap between price and value offers scant protection if growth fails to recover. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
PTCT trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markdown$64.13-12.7%Entry 6
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 12.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 42%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (14 analysts) rates it buy, with a mean price target of $92. Insiders have been net sellers over the past quarter.
2026-09-10Markdown · changed$73.47+3.7%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 42%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (14 analysts) rates it buy, with a mean price target of $92.
2026-08-09Markup$70.85-5.7%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 5.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 42%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (14 analysts) rates it buy, with a mean price target of $92.
2026-07-18Markup$75.14+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 42%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (14 analysts) rates it buy, with a mean price target of $92.
2026-07-03Markup$75.14+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markup$75.14Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
